ilorasertib

an antineoplastic agent and protein kinase inhibitor; structure in first source

Also Known As:

1-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno(3,2-c)pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea; ABT-348; urea, N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno(3,2-c)pyridin-3-yl)phenyl)-N'-(3-fluorophenyl)-

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Albert, Daniel H: 2 articles (08/2015 - 12/2012)
2.	Ansell, Peter: 1 article (08/2015)
3.	Arellano, Martha: 1 article (08/2015)
4.	Garcia-Manero, Guillermo: 1 article (08/2015)
5.	Kadia, Tapan: 1 article (08/2015)
6.	Kantarjian, Hagop: 1 article (08/2015)
7.	Khoury, Hanna Jean: 1 article (08/2015)
8.	Knight, Emily A: 1 article (08/2015)
9.	McKee, Mark D: 1 article (08/2015)
10.	Munasinghe, Wijith: 1 article (08/2015)

Related Diseases

1.	Hematologic Neoplasms (Hematological Malignancy) 08/01/2015 - "This phase 1 trial determined the safety, pharmacokinetics, and preliminary antitumor activity of ilorasertib alone or combined with azacitidine in advanced hematologic malignancies. " 12/01/2012 - "On the basis of its unique spectrum of activity, ABT-348 was evaluated and found effective in representative solid tumor [HT1080 and pancreatic carcinoma (MiaPaCa), tumor stasis] and hematological malignancy (RS4;11, regression) xenografts. " 08/01/2015 - "Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies." 08/01/2015 - "Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models in various hematological malignancies, indicating that pan-Aurora kinase and multiple kinase inhibition may have preferential antileukemic activity. "
2.	Pancreatic Neoplasms (Pancreatic Cancer) 12/01/2012 - "On the basis of its unique spectrum of activity, ABT-348 was evaluated and found effective in representative solid tumor [HT1080 and pancreatic carcinoma (MiaPaCa), tumor stasis] and hematological malignancy (RS4;11, regression) xenografts. "
3.	Neoplasms (Cancer) 12/01/2012 - "These results provide the rationale for clinical assessment of ABT-348 as a therapeutic agent in the treatment of cancer." 12/01/2012 - "On the basis of its unique spectrum of activity, ABT-348 was evaluated and found effective in representative solid tumor [HT1080 and pancreatic carcinoma (MiaPaCa), tumor stasis] and hematological malignancy (RS4;11, regression) xenografts. "
4.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/01/2015 - "Fifty-two patients (median age, 67 years; 35 % with >4 prior regimens) with acute myelogenous leukaemia (AML; n = 38), myelodysplastic syndrome (n = 12), or chronic myelomonocytic leukaemia (n = 2) received 3 or 6 doses of ilorasertib per 28-day cycle and were assigned to arm A (once-weekly oral), B (twice-weekly oral), C (once-weekly oral plus azacitidine), or D (once-weekly intravenous) treatment. "
5.	Leukemia 12/01/2012 - "In vivo inhibition of Aurora B was confirmed in an engrafted leukemia model by observing a decrease in phosphorylation of histone H3 that persisted in a dose-dependent manner for 8 h and correlated with plasma concentration of ABT-348. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
2.	Phosphotransferases (Kinase)
3.	Azacitidine (5 Azacytidine)
4.	Aurora Kinases
5.	Histones (Histone)